Pipeline Novartis gets win for another Avidity muscular dystrophy AOC PharmaphorumNovartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 11, 2026) Pharmaphorum Novartis’ $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy. Rare Disease Read full story Post navigation Previous: SonoThera bags $125M series B to advance safer gene therapiesNext: J&J adds rare disease wAIHA to Imaavy’s potential uses Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
